Chromos Molecular Systems has published data demonstrating that a monoclonal antibody directed against VLA-2, the target for its multiple sclerosis drug can suppress the signs of disease in an animal model.
Subscribe to our email newsletter
In addition, the data validates VLA-2 as a potential target for early therapeutic intervention in the treatment of multiple sclerosis (MS).
“Currently, there are no FDA approved therapies for MS patients suffering from a relapse. CHR-1103 represents a promising new approach for the treatment of MS relapse and disease compared to the existing portfolio of chronically administered treatments,” said Alistair Duncan, president and CEO.
CHR-1103 is a humanized monoclonal antibody being developed as a broad-based anti-inflammatory agent, with an initial focus on the treatment of acute relapses associated with MS. Unlike therapeutics designed to delay or antagonize the initial stages of inflammation, CHR-1103 is designed to reduce and prevent the accumulation of inflammatory cells within inflamed tissues.